Advantage 40 Feline and Bunny Spot-on Solution

Main information

  • Trade name:
  • Advantage 40 Feline and Bunny Spot-on Solution
  • Pharmaceutical form:
  • Spot-on solution
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Advantage 40 Feline and Bunny Spot-on Solution
    France
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • imidacloprid
  • Therapeutic area:
  • Cats, Rabbit

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0389/001
  • Authorization date:
  • 26-10-2011
  • EU code:
  • UK/V/0389/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

Issued:December2011

AN:01256/2010

Page1of7

SUMMARYOFPRODUCTCHARACTERISTICS

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

Advantage40mgfelineandbunnySpot-onsolution[UK]

Advantage40mgSpot-onsolutionforSmallCatsandSmallPetRabbits[AT,DE,FR,

IE,IT]

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

Each0.4mlpipettecontains:

Activesubstance:

Imidacloprid 40mg

Excipient(s):

Butylhydroxytoluene(E321) 0.4mg

Benzylalcohol 332.8mg

Forafulllistofexcipients,seesection6.1.

3. PHARMACEUTICALFORM

Spot-onsolution

Clearyellowtoslightlybrownishsolution

4. CLINICALPARTICULARS

4.1Targetspecies

Catsandpetrabbits

4.2Indicationsforuse,specifyingthetargetspecies

Forcatsoflessthan4kg:

Preventionandtreatmentoffleainfestations

Forpetrabbitsoflessthan4kg:

Treatmentoffleainfestations

Fleasarekilledwithinonedayfollowingtreatment.Onetreatmentpreventsfurtherflea

infestationforthreetofourweeksoncatsanduptooneweekonpetrabbits.The

productcanbeusedaspartofatreatmentstrategyforthecontrolofFleaAllergy

Dermatitis(FAD)incats,wherethishasbeenpreviouslydiagnosedbyaveterinary

surgeon.

Issued:December2011

AN:01256/2010

Page2of7

4.3Contraindications

Donottreatunweanedkittensoflessthan8weeksofage.

Donotuseonrabbitsintendedforhumanconsumption.

Donotuseonpetrabbitsoflessthan10weeksofage.

Donotuseinanimalsthatareknowntobehypersensitivetotheactivesubstanceorany

oftheexcipients.

4.4Specialwarnings

Re-infestationfromemergenceofnewfleasintheenvironmentmaycontinuetooccurfor

sixweeksorlongeraftertreatmentisinitiated.Morethanonetreatmentmaytherefore

berequired,dependingontheleveloffleasintheenvironment.Toaidreductionin

environmentalchallenge,theadditionaluseofasuitableenvironmentaltreatment

againstadultfleasandtheirdevelopingstagesisrecommended.Inordertoreduce

furthertheenvironmentalchallenge,itisrecommendedthatalldogs,catsandrabbitsin

thehouseholdaretreated.Treatmentofnursingqueensanddoescontrolsflea

infestationsonbothdamandoffspring.

Theproductremainseffectiveiftheanimalbecomeswet,forexampleafterexposureto

heavyrain.However,re-treatmentmaybecomenecessary,dependingonthepresence

offleasintheenvironment.Inthesecasesdonottreatmorefrequentlythanonceweekly.

4.5Specialprecautionsforuse

Specialprecautionsforuseinanimals

Thisproductisfortopicaluseandshouldnotbeadministeredorally.

Applyonlytoundamagedskin

Careshouldbetakentoavoidthecontentsofthepipettecomingintocontactwiththe

eyesormouthoftherecipientanimal.

Donotallowrecentlytreatedanimalstogroomeachother.

Specialprecautionstobetakenbythepersonadministeringtheveterinary

medicinalproducttoanimals

Washhandsthoroughlyafteruse.

Washoffanyskincontaminationwithsoapandwater.

Peoplewithknownskinsensitivitymaybeparticularlysensitivetothisproduct.

Avoidcontactoftheproductwiththeeyesormouth.

Iftheproductgetsintoeyesaccidentally,theeyesshouldbethoroughlyflushedwith

water.Ifskinoreyeirritationpersists,ortheproductisaccidentallyswallowed,obtain

medicalattention.

Donoteat,drinkorsmokeduringapplication.

Issued:December2011

AN:01256/2010

Page3of7

4.6Adversereactions(frequencyandseriousness)

Theproductisbittertastingandsalivationmayoccasionallyoccuriftheanimallicksthe

applicationsiteimmediatelyaftertreatment.Thisisnotasignofintoxicationanddisap-

pearswithinsomeminuteswithouttreatment(seealsosection4.9Amountstobe

administeredandadministrationroute).

Inveryrareoccasionsskinreactionssuchashairloss,redness,itchingandskinlesions

mayoccurincatsandrabbits.Agitation, excessivesalivationandnervoussignssuchas

incoordination,tremorsanddepressionhavealsobeenreportedbutexceptionallyin

cats.

4.7Useduringpregnancy,lactationorlay

Sincenoprimaryembryotoxic,teratogenicorreproductivetoxiceffectshavebeen

observedduringthestudieswithimidaclopridonratsandrabbitstheproductcanbe

usedinpregnantorlactatingdoes.Studiesonpregnantandlactatingqueenstogether

withtheiroffspringarelimited.Evidencesofarsuggeststhatnoadverseeffectsareto

beexpectedintheseanimals.

4.8Interactionwithothermedicinalproductsandotherformsofinteraction

Noincompatibilityhasbeenobservedbetweenthisproductattwicetherecommended

doseandthefollowingcommonlyusedveterinaryproducts:lufenuron,pyranteland

praziquantel(cats).Thecompatibilityoftheproductwasalsodemonstratedwithawide

rangeofroutinetreatmentsunderfieldconditionsincludingvaccination.

4.9Amountstobeadministeredandadministrationroute

DosageandTreatmentSchedule

Cat/Rabbit(kgbw) Product Numberof

Pipettes Imidacloprid

(mg/kgbw)

<4kg Advantage40forSmall

CatsandSmallPet

Rabbits 1x0.4ml minimumof10

MethodofAdministration

Removeonepipettefromthepackage.Holdpipetteinanuprightposition,twistandpull

offcap.Usereversedcaptotwistandremovesealfrompipette.

Issued:December2011

AN:01256/2010

Page4of7

AdministrationtotheCat

Partthehaironthecat'sneckatthebaseoftheskulluntiltheskinisvisible.Placethe

tipofthepipetteontheskinandsqueezefirmlyseveraltimestoemptythecontents

directlyontotheskin.

AdministrationtotheRabbit

Partthehairontherabbit’sneckatthebaseoftheskulluntiltheskinisvisible.Placethe

tipofthetubeontheskinandsqueezefirmlyseveraltimestoemptythecontentsdirectly

ontotheskin.

AllSpecies

Theproductisbittertastingandsalivationmayoccasionallyoccuriftheanimallicksthe

applicationsiteimmediatelyaftertreatment.Thisisnotasignofintoxicationand

disappearswithinsomeminuteswithouttreatment.Applicationatthebaseoftheskull

willminimizetheopportunityforthecattolicktheproduct.

Applyonlytoundamagedskin.Donotallowrecentlytreatedanimalstogroomeach

other.

4.10Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

Incats,noadverseclinicalsignswereproducedusingdosesoffivetimesthe

therapeuticlevelweeklyforeightconsecutiveweeks.

Inrabbits,noadverseclinicalsignswereseenusingdosesofupto45mg/kgbody

weight(4timesthetherapeuticlevel)weeklyfor4consecutiveweeks.

Issued:December2011

AN:01256/2010

Page5of7

Inrarecasesofoverdoseorlickingoftreatedfur,nervoussystemdisorders(suchas

twitching,tremors,ataxia,mydriasis,miosis,lethargy)canoccurincats.

Poisoningfollowinginadvertentoraluptakeinanimalsisunlikely.Inthisevent,treatment

shouldbesymptomaticunderveterinarymedicalattention.Thereisnoknownspecific

antidotebutadministrationofactivatedcharcoalmaybebeneficial.

4.11Withdrawalperiod(s)

Donotuseonrabbitsintendedforhumanconsumption.

5. PHARMACOLOGICALPROPERTIES

Pharmacotherapeuticgroup:antiparasiticagent

ATCvetcode:QP53AX17

5.1Pharmacodynamicproperties

Imidacloprid,1-(6-Chloro-3-pyridylmethyl)-N-nitro-imidazolidin-2-ylideneamineisan

ectoparasiticidebelongingtoagroupofchloronicotinylcompounds.Chemically,itis

moreaccuratelydescribedasachloronicotinylnitroguanidine.

Thesubstancehasahighaffinityforthenicotinergicacetylcholinereceptorsinthepost-

synapticregionofthecentralnervoussystem(CNS).Theensuinginhibitionof

cholinergictransmissionininsectsresultsinparalysisanddeath.Duetotheweak

natureoftheinteractionwithmammaliannicotinergicreceptorsitesandthepostulated

poorpenetrationthroughtheblood/brainbarrierinmammals,ithasvirtuallynoeffecton

themammalianCNS.Theminimalpharmacologicalactivityinmammalsissupportedby

safetystudiesinvolvingsystemicadministrationofsub-lethaldosestorabbits,miceand

rats.

Infurtherstudies,inadditiontotheadulticidefleaefficacyofimidacloprid,alarvicidal

fleaefficacyinthesurroundingsofthetreatedpethasbeendemonstrated.Larval

stagesinthepet’ssurroundingsarekilledfollowingcontactwithatreatedanimal.

5.2Pharmacokineticparticulars

Theproductisindicatedforcutaneousadministration.Followingtopicalapplicationin

cats,thesolutionisquicklydistributedovertheanimal.Acutedermalstudiesintherat

andtargetanimaloverdoseandserumkineticstudieshaveestablishedthatsystemic

absorptionisverylow,transientandnotrelevantfortheclinicalefficacy.Thishasbeen

furtherdemonstratedbyastudyinwhichfleaswerenotkilledafterhavingfedon

previouslytreatedanimalsoncetheanimal’sskinandfurhadbeencleanedofallactive

material.

6. PHARMACEUTICALPARTICULARS

6.1Listofexcipients

ButylhydroxytolueneE321

Issued:December2011

AN:01256/2010

Page6of7

Benzylalcohol

Propylenecarbonate

6.2Incompatibilities

Noneknown.

6.3Shelflife

Shelflifeoftheveterinarymedicinalproductaspackagedforsale:

5years

6.4.Specialprecautionsforstorage

Thisveterinarymedicinalproductdoesnotrequireanyspecialstorageconditions.

Keeptheblisterintheoutercarton.

6.5Natureandcompositionofimmediatepackaging

Packsizes 0.4mlsolutionperpipette

Blisterpackcontaining2,3,4,or6unitdosepipettes

Container Whitepolypropylenepipetteswithcaps

Notallpacksizesmaybemarketed.

6.6Specialprecautionsforthedisposalofunusedveterinarymedicinal

productorwastematerialsderivedfromtheuseofsuchproducts

Anyunusedveterinarymedicinalproductorwastematerialsderivedfromsuch

veterinarymedicinalproductsshouldbedisposedofinaccordancewithlocal

requirements.

7. MARKETINGAUTHORISATIONHOLDER

Bayerplc

AnimalHealthDivision

BayerHouse

StrawberryHill

Newbury

Berkshire

RG141JA

8. MARKETINGAUTHORISATIONNUMBER

Vm00010/4177

Issued:December2011

AN:01256/2010

Page7of7

9. DATEOFFIRSTAUTHORISATION

8December2011

10.DATEOFREVISIONOFTHETEXT

December2011

13-12-2018

Evaluation of the safety and efficacy of the organic acids lactic and acetic acids to reduce microbiological surface contamination on pork carcasses and pork cuts

Evaluation of the safety and efficacy of the organic acids lactic and acetic acids to reduce microbiological surface contamination on pork carcasses and pork cuts

Published on: Wed, 12 Dec 2018 Studies evaluating the safety and efficacy of lactic and acetic acids to reduce microbiological surface contamination on pork carcasses pre‐chill and pork meat cuts post‐chill were assessed. Lactic acid treatments consisted of 2–5% solutions at temperatures of up to 80°C applied to carcasses by spraying or up to 55°C applied on cuts by spraying or dipping. Acetic acid treatments consisted of 2–4% solutions at temperatures of up to 40°C applied on carcasses by spraying or o...

Europe - EFSA - European Food Safety Authority Publications

15-11-2018

Safety and efficacy of Monimax® (monensin sodium and nicarbazin) for chickens for fattening and chickens reared for laying

Safety and efficacy of Monimax® (monensin sodium and nicarbazin) for chickens for fattening and chickens reared for laying

Published on: Wed, 14 Nov 2018 The coccidiostat Monimax® (monensin sodium and nicarbazin) is considered safe for chickens for fattening and chickens reared for laying at the highest use level of 50 mg monensin and 50 mg nicarbazin/kg complete feed. This conclusion is extended to chickens reared for laying. For both active substances, the metabolic pathways in the chicken are similar to those in the turkey and rat. Nicarbazin, when ingested, is rapidly split in its two components dinitrocarbanilide (DNC)...

Europe - EFSA - European Food Safety Authority Publications

12-10-2018

FDA advances investigation into whether more than 40 e-cigarette products are being illegally marketed and outside agency's compliance policy

FDA advances investigation into whether more than 40 e-cigarette products are being illegally marketed and outside agency's compliance policy

FDA advances investigation into whether more than 40 e-cigarette products are being illegally marketed and outside agency's compliance policy

FDA - U.S. Food and Drug Administration

11-9-2018

Risk assessment of antimicrobial resistance along the food chain through culture‐independent methodologies

Risk assessment of antimicrobial resistance along the food chain through culture‐independent methodologies

Published on: Mon, 27 Aug 2018 00:00:00 +0200 Antimicrobial resistance (AMR) represents a major challenge for Public Health and the scientific community, and requires immediate and drastic solutions. Acquired resistance to certain antimicrobials is already widespread to such an extent that their efficacy in the treatment of certain life‐threatening infections is already compromised. To date, the emergence and spread of AMR has been attributed to the use, misuse or indiscriminate use of antibiotics as th...

Europe - EFSA - European Food Safety Authority Publications

9-8-2018

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Valsartan Tablets, USP, 40mg, 80mg, 160mg and 320mg Due to The Detection of Trace Amounts of N-Nitrosodimethylamine (NDMA) Impurity, Found in an Active Pharmaceutical Ingredient (API)

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Valsartan Tablets, USP, 40mg, 80mg, 160mg and 320mg Due to The Detection of Trace Amounts of N-Nitrosodimethylamine (NDMA) Impurity, Found in an Active Pharmaceutical Ingredient (API)

As a precautionary measure, Camber Pharmaceuticals, Inc. is voluntarily recalling all unexpired lots of Valsartan Tablets, USP, 40mg, 80mg, 160mg and 320mg to the hospital, retail and consumer level. This recall of multiple batches of Valsartan Tablets was prompted due to the detection of trace amounts of N-Nitrosodimethylamine (NDMA), a possible process impurity or contaminant in an active pharmaceutical ingredient, manufactured by Hetero Labs Limited, Unit – I (API manufacturer).

FDA - U.S. Food and Drug Administration

There are no news related to this product.